Welcome to our dedicated page for PHARM news (Ticker: PHARM), a resource for investors and traders seeking the latest updates and insights on PHARM stock.
Pharming Group N.V. (PHARM) is a global biopharmaceutical company listed on Euronext Amsterdam and Nasdaq that focuses on rare, debilitating, and life‑threatening diseases. Its news flow reflects both commercial performance and clinical development across a portfolio that includes the recombinant C1 esterase inhibitor RUCONEST® for acute hereditary angioedema (HAE) attacks and Joenja® (leniolisib), an oral PI3Kδ inhibitor for activated phosphoinositide 3‑kinase delta syndrome (APDS).
On this page, readers can follow company announcements on quarterly and annual financial results, preliminary revenue updates, and guidance changes, where Pharming explains how demand for RUCONEST® and Joenja® contributes to its revenue mix. The company also issues news about participation in healthcare and investor conferences, such as rare disease summits and global healthcare meetings, where management discusses markets like HAE and APDS.
Pharming’s communications highlight regulatory and clinical milestones, including U.S. FDA Priority Review of a supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years, Phase II proof‑of‑concept trials in primary immunodeficiencies with immune dysregulation, and pivotal studies such as the FALCON trial of KL1333 in mitochondrial DNA‑driven mitochondrial disease. Scientific updates around major congresses feature new clinical, economic, and real‑world data on RUCONEST® and Joenja®.
Investors and followers of PHARM can use this news feed to track developments in Pharming’s rare disease portfolio, including commercial updates, pipeline progress, organizational changes, and index movements such as its promotion to the Euronext AMX® (MidCap) index.
Pharming Group (Euronext: PHARM / Nasdaq: PHAR) announced management will participate in the Jefferies Global Healthcare Conference in London on November 17-20, 2025. Fabrice Chouraqui, Chief Executive Officer, will take part in a Fireside Chat Q&A on Wednesday, November 19 at 10:00 GMT / 11:00 CET. A live webcast and replay will be available via the company website under Upcoming Events and News. Investors seeking one-to-one meetings or more details can contact Investor Relations at investor@pharming.com or coordinate through a Jefferies representative.
Pharming Group (Euronext: PHARM / Nasdaq: PHAR) will report preliminary unaudited Q3 2025 financial results and provide a business update on Thursday, November 6, 2025.
Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET / 07:30 ET. Investors must register in advance for the conference call or webcast; dial-in attendees will receive a unique PIN and only dial-in participants can ask questions. The webcast will be available on the company’s Investors/Financial Documents page and a replay will be posted shortly after the event.
Pharming (Euronext: PHARM; Nasdaq: PHAR) announced that 12 abstracts were accepted for presentation at the ACAAI 2025 Annual Scientific Meeting in Orlando, Florida, November 6-10, 2025.
Five posters cover new clinical, economic and comparative data for RUCONEST in on-demand hereditary angioedema (HAE). Seven posters present real-world effectiveness and pediatric Phase III results for Joenja (leniolisib) and explore pediatric and caregiver burden in APDS.
Selected poster dates/times are on November 7-9, 2025; all ePosters will be available online on ACAAI’s site to registered attendees starting November 6, 2025 at 08:00 EST.
Pharming (Euronext: PHARM; Nasdaq: PHAR) announced an organizational restructuring to accelerate growth and implement a previously disclosed G&A reduction plan.
The plan includes a 20% net reduction in non-commercial and non-medical headcount, primarily at its Netherlands headquarters, and targets 15% lower total G&A or approximately $10 million annually. The company expects one-time restructuring costs of about $7 million to be recorded in Q4 2025. Pharming said it consulted with its Dutch Works Council in line with Dutch labor law.
Pharming Group (NASDAQ:PHAR) announced that the FDA has accepted its supplemental New Drug Application (sNDA) for leniolisib (Joenja®) with Priority Review status. The application seeks approval for treating children aged 4-11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.
The sNDA is supported by positive data from a Phase III study showing improvements in lymphadenopathy and increased naïve B cells over 12 weeks. The FDA has set a PDUFA target date of January 31, 2026. If approved, leniolisib would become the first treatment available for APDS patients under 12 years old globally. The drug is already approved for patients 12 years and older since March 2023.
Pharming Group (Euronext: PHARM; Nasdaq: PHAR) announced its promotion from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective September 22, 2025. The AMX index consists of 25 companies selected based on free-float market capitalization and liquidity.
This promotion marks Pharming's return to the AMX index and reflects the company's strong growth momentum. CEO Fabrice Chouraqui emphasized that this inclusion will enhance the company's visibility and attractiveness to investors as they continue developing into a leading global rare disease company.
Pharming Group (Nasdaq: PHAR) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York, scheduled for September 8-10, 2025. CEO Fabrice Chouraqui will deliver a presentation on Monday, September 8 at 1:30pm EDT/19:30 CEST.
Investors can access the live webcast and replay through Pharming's website in the "Upcoming Events" and "News" sections. One-on-one meetings with management can be arranged through Investor Relations or H.C. Wainwright representatives.
Pharming Group (NASDAQ: PHAR) has appointed Kenneth Lynard as its new Chief Financial Officer, effective October 1, 2025. Lynard brings over 20 years of global leadership experience in the life sciences industry, with significant expertise in financial and operational transformation.
Lynard's most recent roles include CFO positions at Schoeller Allibert and Zentiva. Notably, during his five-year tenure at Gilead Sciences as Senior VP and CFO of Global Commercial Operations, R&D and Manufacturing, he helped triple the business following the Pharmasset acquisition. His appointment follows Pharming's strong first half 2025 results and aims to strengthen the company's financial leadership as it pursues its vision of becoming a leading global rare disease company.
Pharming Group (NASDAQ:PHAR) announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, USA. CEO Fabrice Chouraqui will deliver a presentation on Tuesday, August 12, 2025, at 12:00 PM EDT/18:00 CEST.
Investors interested in one-on-one meetings with Pharming's management team can arrange them through the company's Investor Relations team or their Canaccord Genuity representative.
Pharming Group (NASDAQ:PHARM) reported strong Q2 2025 financial results with total revenues increasing 26% to US$93.2 million. The growth was driven by RUCONEST® revenue rising 28% to US$80.4 million and Joenja® revenue growing 15% to US$12.8 million.
The company achieved an operating profit of US$10.8 million in Q2 2025, compared to a US$3.1 million loss in Q2 2024. Cash position strengthened to US$130.8 million, up from US$108.9 million in Q1 2025. Based on strong performance, Pharming raised its 2025 revenue guidance to US$335-350 million.
A significant study published in Cell suggests APDS prevalence may be up to 100 times higher than previously estimated, potentially expanding Joenja's addressable market. The company also submitted a new drug application for leniolisib in Japan and launched Joenja® in the UK with first patients on commercial therapy.